NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis

BioMarin Pharmaceutical Inc. (BMRN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BMRN

$55.21

−$1.23 (−2.18%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BMRN with… →

BMRN Key Statistics

As of Oct 21, 2026
Trading
Open
$56.40
Previous Close
$56.44
Day's Range
54.91–57.00
52-Week Range
49.26–70.98
Volume
2.51M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.22
Valuation
Market Cap
$10.69B
P/E Ratio
149.22
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
8.61
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.33
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.14
EPS (ttm)Profit attributable to each share over the last twelve months.
0.37
Financials (FY)
Revenue (FY)
$3.22B+12.87%
Net Income (FY)
$348.90M−18.26%
Profit marginThe share of revenue left as profit after all costs and taxes.
2.14%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
193.57M
1-Year Return
+2.60%
Dividend and dates
Earnings Date
October 26, 2026
Avg Volume
2.20M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BMRN closed at $55.21, +2.60% over 1 year.

BioMarin Pharmaceutical Inc. (BMRN) has a market capitalization of $10.69B.

In fiscal 2025, BMRN reported revenue of $3.22B.

BMRN Stock Return by Calendar Year

BioMarin Pharmaceutical Inc. (BMRN) 10-year return: what $10,000 became

1 year
$10,000 $10,260
+2.60%
5 years
$10,000 $7,353
−26.47%
10 years
$10,000 $6,710
−32.90%

If you had invested $10,000 in BioMarin Pharmaceutical Inc. (BMRN) 10 years ago, at the close on October 21, 2016, it would have been worth $6,710 at the close on October 21, 2026: −32.90% in total, −3.91% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−7.10%
2025−9.58%
2024−31.83%
2023−6.83%
2022+17.14%
2021+0.75%
2020+3.71%
2019−0.70%
2018−4.51%
2017+7.64%
2016 (partial year)−16.34%

As of October 21, 2026.

BMRN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$3.22B$348.90M10.8%
2024$2.85B$426.86M15.0%
2023$2.42B$167.65M6.9%
2022$2.10B$141.56M6.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$3.22B$2.50B$409.50M$348.90M10.8%
2024$2.85B$2.27B$474.24M$426.86M15.0%
2023$2.42B$1.89B$185.78M$167.65M6.9%
2022$2.10B$1.59B$57.41M$141.56M6.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BMRN Valuation vs Biotechnology Median

Median of 608 stocks
MetricBMRNBiotechnology medianvs median
P/E149.2216.609.0x the median
P/S ratio3.1413.300.2x the median
Profit margin2.14%−38.31%40.5 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

BioMarin Pharmaceutical Inc. (BMRN) is capitalised at $10.69B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 3,221.

BMRN last closed at $55.21 on October 21, 2026. That is −$1.23 (−2.18%) against the previous close. Over the past 52 weeks the price has ranged from $49.26 to $70.98. The latest close sits 12.08% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $3.22B. Against the prior fiscal year total of $2.85B, that is a change of +12.87%. The same year closed with net income of $348.90M. That is −18.26% against the prior fiscal year. The reported profit margin is 2.14%. That is 40.5 percentage points above the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to 0.37.

Across the 4 fiscal years on file, revenue moves from $2.10B in 2022 to $3.22B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 149.22 times earnings. That is 9 times the Biotechnology median of 16.6. On forward earnings the ratio is 8.61. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.33. Measured against sales, the shares trade at 3.14 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is +2.60%. Measured over 10 years, that is −3.91% a year compounded. The reported beta is 0.22. Annualized volatility over the trailing 10 years is 35.05%.

Growth & Income

The record shows no dividend for BMRN.

2026 is still running; the total return is −7.10% year to date. The strongest complete calendar year on file is 2022 at +17.14%; the weakest is 2024 at −31.83%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

BioMarin Pharmaceutical Inc. (BMRN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BioMarin Pharmaceutical Inc. BMRN $10.69B 149.2
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. BioMarin Pharmaceutical Inc. trades at a P/E of 149.2.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Visit website →